ATX-304 and SR9009 are each a small molecule rather than a peptide.
Same target, different schedules: ATX-304 once daily in the trial; SR9009 not established.
| Comparison | ATX-304 (O-304) O-304 · ATX304 | SR9009 (Stenabolic) Stenabolic · SR-9009 |
|---|---|---|
| How it works | How it works AMPK is the low-energy alarm. Most things that activate it do so by making the cell short of energy. | How it works SR9009 is not a peptide and not a SARM, though it is sold alongside both. |
| What it is | An exercise mimetic that got through a phase 2a trial and then went quiet. | A body clock drug sold as a workout replacement, with an oral absorption problem. |
| Status | Research only | Research only |
| Typical dose | 400 mg per day | 20–30 mg per day |
| How often | Once daily in the trial | Not established |
| Stays active | Long in rodents, unverified in humans | Nothing published |
| Dose comes from | Clinical trial protocol | Community practice |
| Cycled? | Continuous in the one human trial Clinical trial protocol | Not established No established range |
| What it does | ||
| Drug class | Pan-AMPK activator (oral, not a peptide) | REV-ERB agonist (small molecule) |
| Used for | An oral AMPK activator sold as an exercise mimetic, with one real human trial behind it and nothing since. | Sold orally for endurance, fat loss and metabolic effects. |
| Receptors hit | — | — |
| Numbers | ||
| Full dose line | 400 mg per day | Research only |
| Why that cycle | The phase 2a trial ran it daily for 28 days alongside metformin, with no break. Nothing longer has been published, so there is no evidence either way about extended use. | No schedule has been studied for this compound in people. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | Not disclosed | Not disclosed |
| Common vial | — | — |
| Before you start | ||
| Route | By mouth (oral) | By mouth (oral) |
| Do not use if | Pregnancy and breastfeeding Taking metformin or other glucose-lowering drugs, without medical supervision, since the trial combined them deliberately Any condition affecting blood sugar control Banned in drug-tested sport | Pregnancy or breastfeeding Anyone competing in drug-tested sport Anyone who wants established safety data, because none exists for this compound in humans |
What separates them
Proof behind the dose. ATX-304 has a dose from a clinical trial protocol. SR9009 has a range that comes from community practice, with no published human study behind it.
What doesn't differ: They are both taken the same way (by mouth) and aimed at the same thing (endurance & fat loss). Neither has a measured effect size from a published trial, so there is no number to rank them on.
What people actually report
ATX-304 (O-304)
- One published human trial exists, it was small, and it was a proof-of-concept study in people already taking metformin.
- AMPK activators are banned in drug-tested sport as metabolic modulators, the same class as AICAR.
- Vendor CAS numbers and salt forms are inconsistent between sellers, so identity is not something to take on trust.
- Signs of low blood sugar such as shakiness, sweating, confusion or a pounding heartbeat
- Persistent vomiting or severe stomach pain
SR9009 (Stenabolic)
- The effect data comes from injected animals while the product is sold as an oral capsule.
- Banned in drug-tested sport.
- Signs of an allergic reaction, including spreading hives, facial or throat swelling, or trouble breathing
- Anything unusual, since there is no known safety profile to compare it against
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.